Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.52 ^USD	0.00%		-1.84%	+132.79%

Apr. 15	Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target	MT
Mar. 18	Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital	CI

Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder

October 24, 2023 at 07:30 am EDT

Mind Medicine (MindMed) Inc. announced that it has completed enrollment of Study MMED007, the Company's Phase 2a study evaluating repeated low-dose administration of MM-120 (lysergide D-tartrate) for the treatment of adults with ADHD. MMED007 is a multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MM-120 (20 mg) compared with a placebo administered orally twice weekly for 6 weeks in adults between the ages of 18 and 65 with ADHD.

Latest news about Mind Medicine (MindMed) Inc.

Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target	Apr. 15	MT
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital	Mar. 17	CI
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk	Mar. 08	MT
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder	Mar. 08	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Mar. 07	MT
Sector Update: Health Care Stocks Stronger in Afternoon Trading	Mar. 07	MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating	Mar. 07	MT
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump	Mar. 07	MT
Transcript : Mind Medicine Inc. - Special Call	Mar. 07
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder	Mar. 07	CI
Mind Medicine Inc. announced that it expects to receive $75 million in funding from Deep Track Capital, LP, Commodore Capital	Mar. 06	CI
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept	Feb. 29	MT
Transcript : Mind Medicine Inc., 2023 Earnings Call, Feb 28, 2024	Feb. 28
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024	Jan. 08	CI
Mind Medicine Says MM-120 Shows Significant Dose-Dependent Improvements in Phase 2b Trial on Anxiety Disorder	Dec. 14	MT
Transcript : Mind Medicine Inc. - Special Call	Dec. 14
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	Dec. 14	CI
Transcript : Mind Medicine Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder	23-10-24	CI
Mind Medicine Completes Enrollment and Dosing in Study Mmed008	23-09-12	CI
Mind Medicine Inc. Secures $50.0 Million Credit Facility with K2 HealthVentures	23-08-14	CI
Mind Medicine Inc. announced that it has received $15 million in funding	23-08-10	CI

Chart Mind Medicine (MindMed) Inc.

Duration

Period

More charts

Company Profile

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Sector

Biotechnology & Medical Research

Calendar

2024-05-03 - American Psychiatric Association Congress - Dan Karlin, MD

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.52 USD

Average target price

30.86 USD

Spread / Average Target

+262.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MIND MEDICINE (MINDMED) INC.	+132.79%	601M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research